Judge Halts Alzheimer’s Drug Swap
A drug manufacturer on Thursday was ordered by a judge to halt plans to discontinue its widely used Alzheimer’s medication, allegedly in an effort to drive patients to a newer patented drug.
Attorney General Eric Schneiderman alleges anti-trust and state law violations by Actavis to avoid losses from generic alternatives coming out next year. The company has said its new drug Namenda XR is better than the old Namenda. They are appealing, with a hearing set for Monday.
This article appeared in print on page 4 of edition of Hamodia.
To Read The Full Story
Are you already a subscriber?
Click "Sign In" to log in!
Become a Web Subscriber
Click “Subscribe” below to begin the process of becoming a new subscriber.
Become a Print + Web Subscriber
Click “Subscribe” below to begin the process of becoming a new subscriber.
Renew Print + Web Subscription
Click “Renew Subscription” below to begin the process of renewing your subscription.
